表纸
市场调查报告书
商品编码
234470

抗体相关的各种联盟契约 - 契约条件、协定内容 (2014~2019年):资本交易趋势、企业、财务状况

Global Antibody Partnering Terms and Agreements 2015-2022

出版日期: | 出版商: Current Partnering, a division of Wildwood Ventures Limited | 英文 1000+ Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

本报告提供抗体相关的各种资本交易/事业联盟的契约缔结相关分析,近几年的各种契约的缔结趋势,及大规模契约及大医药品经营者的契约概要,各契约类型/各临床实验阶段/各技术/各治疗内容的契约一览等资讯汇整,为您概述为以下内容。

摘要整理

第1章 简介

第2章 抗体相关的各种交易趋势

  • 简介
  • 近几年的抗体相关的事业联盟数量
  • 最活跃的,抗体相关的交易主体
  • 抗体相关的事业联盟:各交易类型
  • 抗体相关的事业联盟:各治疗领域
  • 抗体相关的事业联盟:交易条件
    • 交易总额 (headline values)
    • 预付款金
    • 阶段性付款
    • 权利金费率

第3章 抗体相关的主要交易

  • 简介
  • 代表性资本交易 - 交易金额

第4章 抗体相关的最活跃的交易主体

  • 简介
  • 抗体相关的最活跃的交易主体
  • 最活跃的交易主体:企业简介

第5章 抗体相关的契约缔结的一览

  • 简介
  • 签下的合约一览 (名录)

第6章 抗体相关的交易趋势:各技术种类

第7章 抗体相关的资源中心

  • 抗体相关的联网数据库
  • 抗体相关的活动/会议
  • 抗体相关的参考文献

附录

  • 附录 (1) - 抗体相关的资本交易:各企业 (ABC顺序)
  • 附录 (2) - 抗体相关的资本交易:各临床实验阶段
    • 药物研发
    • 前临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 申请登记
    • 已上市
    • 剂型
  • 附录 (3) - 抗体相关的资本交易:各交易类型
    • 资产购买
    • 权利转让
    • 大医药品企业的对外授权
    • 共同开发
    • 共同研究开发 (R&D)
    • 共同行销
    • 共同促销
    • CRADA (共同研究开发契约)
    • 交叉授权
    • 开发
    • 流通
    • 股票购买
    • 评估
    • 转让
    • 合资企业 (合资企业)
    • 授权
    • 贷款
    • 制造
    • 行销
    • 材料转移
    • 选择
    • 推销
    • 研究
    • 和解调停
    • 衍生公司
    • 再授权
    • 供给
    • 技术转移
    • 契约解除
  • 附录 (4) - 抗体相关的资本交易:各治疗领域
    • 心血管
    • 中枢神经系统
    • 牙科
    • 皮肤科
    • 消化器官
    • 血液
    • 住院治疗
    • 免疫
    • 感染疾病
    • 代谢
    • 肌肉骨骼系统疾病
    • 产科
    • 肿瘤 (癌症)
    • 眼科
    • 罕见疾病
    • 小儿科
    • 精神科
    • 呼吸系统
  • 附录 (5) - 资本交易的种类:定义

关于Wildwood Ventures

目录
Product Code: CP2113

The Global Antibody Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies
  • Bispecific antibodies
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
  • This report contains over 1900 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
  • The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2015.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

Global Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Antibody contracts enter into by the leading 25 bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering Terms and Agreements 2015 to 2022 includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1900 Antibody online deal records
  • The leading Antibody deals by value since 2015
  • Most active Antibody dealmakers since 2015
  • The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2015 to 2022, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 1900 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Antibody Partnering 2015-2022 provides the reader with the following key benefits:

  • In-depth understanding of antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 1900 actual antibody deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual antibody contracts enter into by the leading companies
  • Identify leading antibody deals by value since 2015
  • Identify the most active antibody dealmakers since 2015
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody partnering over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody partnering by deal type
  • 2.5. Antibody partnering by therapy area
  • 2.6. Deal terms for antibody partnering
    • 2.6.1 Antibody partnering headline values
    • 2.6.2 Antibody deal upfront payments
    • 2.6.3 Antibody deal milestone payments
    • 2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Appendices

  • Appendix 1 - Antibody deals by company A-Z
  • Appendix 2 - Antibody deals by stage of development
  • Appendix 3 - Antibody deals by deal type
  • Appendix 4 - Antibody deals by therapy area
  • Appendix 5 - Deal type definitions
  • Appendix 6 - Further reading on dealmaking

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Antibody partnering since 2015
  • Figure 3: Active antibody dealmaking activity since 2015
  • Figure 4: Antibody partnering by deal type since 2015
  • Figure 5: Antibody partnering by disease type since 2015
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2015
  • Figure 11: Most active antibody dealmakers since 2015